Parathyroid Hormone-related Peptide-producing Multiple Myeloma and Renal Impairment
-
- Kinomura Masaru
- Department of Nephrology, Kurashiki Central Hospital, Japan
-
- Shimada Noriaki
- Department of Nephrology, Kurashiki Central Hospital, Japan
-
- Nishikawa Mana
- Department of Nephrology, Kurashiki Central Hospital, Japan
-
- Omori Kazuyoshi
- Department of Nephrology, Kurashiki Central Hospital, Japan
-
- Jo Tomoyasu
- Department of Haematology/Oncology, Kurashiki Central Hospital, Japan
-
- Ueda Yasunori
- Department of Haematology/Oncology, Kurashiki Central Hospital, Japan
-
- Notohara Kenji
- Department of Anatomic Pathology, Kurashiki Central Hospital, Japan
-
- Kitazawa Riko
- Department of Molecular Pathology, Ehime University Graduate School of Medicine, Japan
-
- Kitazawa Sohei
- Department of Molecular Pathology, Ehime University Graduate School of Medicine, Japan
-
- Fukushima Masaki
- Department of Internal Medicine, Shigei Medical Research Hospital, Japan
-
- Asano Kenichiro
- Department of Nephrology, Kurashiki Central Hospital, Japan
この論文をさがす
抄録
A 68-year-old man was hospitalized and examined for renal impairment. A laboratory analysis showed hypercalcemia. Although the serum parathyroid hormone and serum 1-25(OH)2 vitamin D3 levels were not elevated, the serum parathyroid hormone-related peptide (PTHrP) level was increased. Immunoelectrophoresis of the urine and bone marrow aspiration indicated multiple myeloma (MM). He was diagnosed with the coexistence of cast nephropathy and light chain deposition disease by a renal biopsy. Notably, PTHrP expression was detected in the myeloma cells based on immunohistochemistry and in situ hybridization. It is therefore important to examine the PTHrP concentration in MM patients with hypercalcemia.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 54 (23), 3029-3033, 2015
一般社団法人 日本内科学会
